文献速递神经免疫

利妥昔单抗对多发性硬化视网膜萎缩的调节作用

Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis.
PubMed 文献 · Neurology · 2021-04-07

这项观察性研究对接受利妥昔单抗治疗的复发缓解型多发性硬化患者进行系列OCT扫描,并与接受醋酸格拉替雷、那他珠单抗治疗的患者及健康对照比较GCIPL萎缩速率。结果显示利妥昔单抗治疗期间GCIPL萎缩速率与GA、那他珠单抗治疗者相似,但快于健康对照;治疗最初12个月萎缩速率较快,之后减慢。提示利妥昔单抗可能调节视网膜萎缩,神经保护效应或需12个月显现。

要点

  • 利妥昔单抗治疗RRMS患者GCIPL萎缩速率为-0.28±0.11 µm/y,与GA和那他珠单抗治疗者相似。
  • 利妥昔单抗治疗者GCIPL萎缩快于健康对照(-0.15±0.03 µm/y,p=0.006)。
  • 治疗最初12个月GCIPL萎缩速率较快,之后减慢至-0.14±0.13 µm/y。

核心结论

  • 利妥昔单抗可调节RRMS患者的视网膜萎缩,治疗12个月后GCIPL萎缩速率与那他珠单抗治疗者及健康对照相似。

研究设计与样本

  • 观察性研究,纳入接受单一疾病修饰治疗的RRMS患者和健康对照,进行中位2.8年的系列OCT随访,采用线性混合效应回归分析。

主要发现

  • 利妥昔单抗组(n=35)GCIPL萎缩速率为-0.28±0.11 µm/y,与GA组(n=49;-0.33±0.05 µm/y;p=0.69)和那他珠单抗组(n=88;-0.17±0.10 µm/y;p=0.13)相似,但快于健康对照(n=78;-0.15±0.03 µm/y;p=0.006)。
  • 利妥昔单抗治疗最初12个月GCIPL萎缩速率较之后快0.55±0.23 µm/y(n=25;p=0.02),之后期间萎缩速率为-0.14±0.13 µm/y。

关键数值与推荐

  • 利妥昔单抗组GCIPL萎缩速率-0.28±0.11 µm/y;GA组-0.33±0.05 µm/y(p=0.69);那他珠单抗组-0.17±0.10 µm/y(p=0.13);健康对照-0.15±0.03 µm/y(p=0.006)。
  • 利妥昔单抗治疗最初12个月与之后GCIPL萎缩速率差异为0.55±0.23 µm/y(n=25;p=0.02),之后期间为-0.14±0.13 µm/y。

临床怎么用

  • 对RRMS患者使用利妥昔单抗时,应知晓其视网膜萎缩的神经保护效应可能在治疗12个月后才更明显。

局限性

  • 本研究为观察性研究,证据等级为Class IV,样本量有限,结果需更大规模研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the effects of rituximab on retinal atrophy in patients with relapsing-remitting multiple sclerosis (RRMS), we performed serial optical coherence tomography (OCT) scans among a cohort of patients with RRMS on rituximab and compared rates of ganglion cell + inner plexiform layer (GCIPL) atrophy to those observed among age- and sex-matched glatiramer acetate (GA)-and natalizumab-treated patients with RRMS and healthy controls (HCs). METHODS: In this observational study, patients with RRMS treated with a single disease-modifying therapy and HCs were followed with serial OCT for a median duration of 2.8 years. Participants with uncontrolled hypertension, diabetes mellitus, or glaucoma, and eyes with optic neuritis ≤6 months prior to baseline OCT, or during follow-up, were excluded. Statistical analyses were performed using linear mixed-effects regression. RESULTS: During the overall follow-up period, rates of GCIPL atrophy were -0.28 ± 0.11 µm/y among rituximab-treated patients with RRMS (n = 35). This was similar to GA-treated (n = 49; -0.33 ± 0.05 µm/y; p = 0.69) and natalizumab-treated patients (n = 88; -0.17 ± 0.10 µm/y; p = 0.13) and faster than HCs (n = 78; -0.15 ± 0.03 µm/y; p = 0.006). Rituximab-treated patients exhibited 0.55 ± 0.23 µm/y faster rates of GCIPL atrophy during the first 12 months of treatment, relative to afterwards (n = 25; p = 0.02), during which period GCIPL atrophy rates were -0.14 ± 0.13 µm/y. CONCLUSIONS: Retinal atrophy in RRMS is modulated by rituximab. Greater attenuation of retinal atrophy may occur after 12 months of rituximab treatment, following which time GCIPL atrophy rates are similar to those observed among natalizumab-treated patients with RRMS and HCs. Our findings raise the possibility that the neuroprotective therapeutic response with rituximab in RRMS may take up to 12 months, which should be confirmed by larger studies. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence on the difference in rate of change of the GCIPL thickness in patients with RRMS comparing rituximab to other disease-modifying therapies.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Lambe J, Risher H, Filippatou AG, et al. Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis. Neurology. 2021. PMID: 33827962. doi:10.1212/WNL.0000000000011933

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。